SCHEMBL27078201

SCHEMBL27078201

COC(=O)c1ccc(C(C)NC(=O)C2(c3ccc(OCc4ccccc4)cc3)CCOCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.49
▸ ACACB O00763 4/20 0.48
▸ TP53 P04637 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ POLB P06746 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ F7 P08709 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ ALOX5 P09917 1/20 0.44
▸ MMP1 P03956 1/20 0.44
▸ MMP13 P45452 1/20 0.44
▸ MRGPRX4 Q96LA9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27078197 1.00 ALDH1A1 (0.49) ALDH1A1ACACBTP53HTTPOLB
SCHEMBL23163958 0.93 RXRA (0.52) ALDH1A1ACACBTP53HTTPOLB
SCHEMBL23163961 0.93 RXRA (0.52) ALDH1A1ACACBTP53HTTPOLB
SCHEMBL28749419 0.92 ACACB (0.50) ACACBCYP2C9CYP2C19NPSR1KMT2A
SCHEMBL28749417 0.92 ACACB (0.50) ACACBCYP2C9CYP2C19NPSR1KMT2A
SCHEMBL23164065 0.91 ALDH1A1 (0.47) ALDH1A1TP53HTTPOLBCYP2C9
SCHEMBL23164063 0.91 ALDH1A1 (0.47) ALDH1A1TP53HTTPOLBCYP2C9
SCHEMBL23163608 0.90 ALDH1A1 (0.47) ALDH1A1TP53HTTPOLBCYP2C9
SCHEMBL23163611 0.90 ALDH1A1 (0.47) ALDH1A1TP53HTTPOLBCYP2C9
SCHEMBL23164208 0.90 ALOX5 (0.47) ALDH1A1ACACBTP53HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists DOMAIN THERAPEUTICS (FR) 2026-01-20 — — US disclosed
EP-4038052-B1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2024-02-07 — — EP disclosed
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-12-01 — — US disclosed
CN-114555573-A Prostaglandin E2(PGE2)EP4Receptor antagonists 多曼治疗学公司 2022-05-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists PTGER1, PTGER4, PTGER3 ALDH1A1 687/4885ACACB 1718/4885TP53 4195/4885
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER2 ALDH1A1 950/4885ACACB 2579/4885TP53 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback